| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial |
| Creator | Munzone et al. |
| Author | E. Munzone |
| Author | A. Giobbie-Hurder |
| Author | B. A. Gusterson |
| Author | E. Mallon |
| Author | G. Viale |
| Author | B. Thürlimann |
| Author | B. Ejlertsen |
| Author | G. MacGrogan |
| Author | F. Bibeau |
| Author | G. Lelkaitis |
| Author | K. N. Price |
| Author | R. D. Gelber |
| Author | A. S. Coates |
| Author | A. Goldhirsch |
| Author | M. Colleoni |
| Abstract | BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years. RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06]. CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease. CLINICALTRIALSGOV: NCT00004205. |
| Publication | Annals of Oncology: Official Journal of the European Society for Medical Oncology |
| Volume | 26 |
| Issue | 12 |
| Pages | 2442-2449 |
| Date | Dec 2015 |
| Journal Abbr | Ann. Oncol. |
| Language | eng |
| DOI | 10.1093/annonc/mdv391 |
| ISSN | 1569-8041 |
| Library Catalog | PubMed |
| Extra | PMID: 26387144 PMCID: PMC4658543 |
| Tags | Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, breast cancer, Breast Neoplasms, Carcinoma, Ductal, Breast, Chemotherapy, Adjuvant, clinic, Cohort Studies, cribriform, Disease-Free Survival, Female, Follow-Up Studies, Humans, letrozole, Middle Aged, mucinous, Neoplasm Recurrence, Local, Nitriles, Tamoxifen, Treatment Outcome, Triazoles, tubular |
| Date Added | 2018/11/13 - 17:26:13 |
| Date Modified | 2019/05/21 - 14:51:16 |
Institut de Recherche en Cancérologie de
